Myriad Is Angling for Gene Dominance

Myriad (MYGN) profits from a variety of tests designed to detect hereditary cancer, making the company a key player in the quest for personalized medicine.

Feb 14, 2014 at 6:30PM

Competitors challenged Myriad Genetics(NASDAQ:MYGN) top selling test for BRCA1 or BRCA2 gene mutation associated with hereditary breast and ovarian cancer last year, but that didn't stop Myriad from putting up big sales and profit growth in the fourth quarter.  

New tests for lung cancer and melanoma and ongoing growth for BRCA testing, thanks in part to ongoing late stage trials for BRCA targeting drugs from AstraZeneca and BioMarin (NASDAQ:BMRN), could make for a busy 2014 too.

MYGN Revenue (TTM) Chart

MYGN Revenue (TTM) data by YCharts

What's at stake?
Personalized medicine is one of the hottest areas for drug development. Identifying over or under expressing proteins, and turning on or off key receptors, offers an intriguing step forward in transforming cancer into a chronic disease.

Some of the biggest advances in personalized medicine are occurring in breast and ovarian cancer -- two forms of cancer with a significant unmet need. Discoveries by AstraZeneca, BioMarin, and AbbVie (NYSE:ABBV) offer new hope for patients given between 20% and 25% of all diagnosed patients possess mutated BRCA genes.

These new PARP-inhibiting drugs offer upside to Myriad because its BRACAnalysis tool is being used to identify patients most likely to benefit from treatment. AstraZeneca is using the tool in its phase 3 trial of Olaparib in ovarian cancer following a retrospective study showing progression free survival for patients treated with the drug was 11.2 months in a mid stage trial, versus 4.3 months for patients in the placebo group. BioMarin is similarly using BRACAnalysis in its phase 3 trial studying BMN-673 as a breast cancer treatment. In mid stage trials, 50% of patients treated with BMN-673 responded to the drug.

AbbVie is also using BRACAnalysis for its PARP-inhibiting drug, Veliparib.  Veliparib is currently in phase 2 trials for breast cancer. And Johnson & Johnson is using BRACAnalysis in its phase 3 trial of its cancer drug Yondelis.

Despite these promising compounds still being in trials, Myriad's BRACAnalysis is already making Myriad big money. BRACAnalysis sales grew 28% to $141 million in the most recent quarter, accounting for 70% of the company's sales.

Growing the business
Creating a one-stop shop for detecting gene defects associated with cancer is Myriad's ultimate goal. The company is expanding the use of its existing tests, launching new products, and combining tests to create more comprehensive offerings.

One of its most successful products this year was its BART test. BART detects BRAC large rearrangement, which happens in less than one percent of BRAC tested patients. BART won inclusion in guidelines from the National Comprehensive Cancer Network last year, helping drive sales 57% higher year-over-year to $24.7 million in the most recent quarter. Sales of Myriad's Colaris family of hereditary colon cancer tests are also growing quickly; increasing 29% year-over-year to $15.6 million last quarter.

The September launch of myRisk, a more comprehensive cancer screening test, may insulate the company from competitors challenging BRACAnalysis. Sales of myRisk got off to a good start last quarter, generating $11.5 million in sales. Sales of myRisk should climb more this year given Myriad recently presented data showing myRisk detected 52% more patients at high risk of hereditary breast and ovarian cancer than testing for BRCA1 and BRCA2 mutation alone.

Fool-worthy final thoughts
Not only is Myriad selling more tests, it's also seeing more of those sales fall to the bottom line. During the fourth quarter, its operating margin grew by 3.4% to 40.7%. The boost translated into earnings per share of $0.66, up 57% year-over-year last quarter. Results for the full year were also strong.  Sales rose 44% to $406 million and EPS expanded 72% to $1.33.

Investors should keep an eye on results this year to see if Myriad's newest products, myPlan for lung cancer and myPath for melanoma, gain traction. It will also be interesting to see if European sales benefit from overseas launches of myRisk and myPath. If so, Myriad may be able to over-deliver on its recently boosted guidance for $740 million to $750 million in sales and $2.09 to $2.12 per share in earnings for 2014.

Three stocks for the long-term investor
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Market, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisor's, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers